ir.versartis.com
Investor Overview - VersartisThe Investor Relations website contains information about Versartis business for stockholders, potential investors, and financial analysts.
http://ir.versartis.com/
The Investor Relations website contains information about Versartis business for stockholders, potential investors, and financial analysts.
http://ir.versartis.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.2 seconds
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
8
SITE IP
206.200.251.19
LOAD TIME
0.198 sec
SCORE
6.2
Investor Overview - Versartis | ir.versartis.com Reviews
https://ir.versartis.com
The Investor Relations website contains information about Versartis business for stockholders, potential investors, and financial analysts.
ir.versartis.com
Analyst Coverage - Versartis
http://ir.versartis.com/analysts.cfm
Annual Reports and Proxies. Versartis is covered by the following analysts. John Newman, Ph.D. Yigal Nochomovitz, Ph.D. Vamil Divan, M.D. Please note that any opinions, estimates or forecasts regarding Versartis's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Versartis or its management. Versartis does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Investor Overview - Versartis
http://ir.versartis.com/index.cfm
Annual Reports and Proxies. Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA. 4:00 PM ET on Nov 9, 2016. Delayed at least 20 minutes. Nov 7, 2016. Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS and IGF Society. Nov 3, 2016.
Key Ratios - Versartis
http://ir.versartis.com/financials-keyratios.cfm
Annual Reports and Proxies.
Corporate Governance - Versartis
http://ir.versartis.com/corporate-governance.cfm
Annual Reports and Proxies. File is in Briefcase. File is in Briefcase. Nominating and Corporate Governance Committee Charter. File is in Briefcase. File is in Briefcase. File is in Briefcase. Add file to Briefcase.
Events & Presentations - Versartis
http://ir.versartis.com/eventdetail.cfm?EventID=160348
Annual Reports and Proxies. Bank of America Merrill Lynch 2015 Health Care Conference. May 13, 2015. Location: Las Vegas, Nevada.
TOTAL PAGES IN THIS WEBSITE
20
Versartis, Inc. - VRS-317
http://www.versartis.com/content/productpipeline/vrs-317.htm
Somavaratan is Versartis' investigational, novel, long-acting form of recombinant human growth hormone (rhGH). This fusion protein consists of rhGH and specific sequences of naturally-occurring hydrophilic amino acids based on a proprietary XTEN. Growth hormone deficiency in children and adults. Phase 1 clinical trial in adult patients with growth hormone deficiency (completed). Phase 2 clinical trial in adult patients with growth hormone deficiency (enrollment complete). August 2012, 101 (8): 2744-2754.
Versartis, Inc. - Product Pipeline
http://www.versartis.com/content/productpipeline/overview.htm
Versartis is interested in exploring partnerships to accelerate the development process and maximize the commercial potential for our products. To learn more about opportunities to partner with Versartis, please contact:. SVP, Corporate Development.
Versartis, Inc. - About Versartis
http://www.versartis.com/content/aboutus/overview.htm
Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA. Develop, manufacture and commercialize novel medicines to transform treatment for patients with endocrine disorders. New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy, fewe...
Versartis, Inc. - Contact Us
http://www.versartis.com/content/careers/index.htm
At Versartis, we are seeking individuals who share our passion for developing long-acting therapeutic proteins for the treatment of endocrine disorders. If this sounds like a place where you would like to work, click on the link below to learn more about the specific opportunities we have available.
Versartis, Inc.
http://www.versartis.com//index.htm
Dedicated to developing treatment alternatives for patients. New compounds developed using the XTEN technology are expected to provide improvement in outcomes such as enhanced efficacy, fewer side effects, improved patient adherence and convenience, and enhanced stability. We are committed to building a first class organization to develop and commercialize somavaratan (VRS-317) and, most importantly, change the lives of people living with the burden of daily injection therapy for the replacement of hGH.
Versartis, Inc. - Press Releases
http://www.versartis.com/content/news/pressreleases.htm
Versartis, Inc. - Senior Management
http://www.versartis.com/content/aboutus/seniormanagement.htm
President and Chief Executive Officer. Joshua T. Brumm. Colin Hislop, MD. Senior Vice President, Corporate Development. Shane M. Ward. Senior Vice President, Legal and Compliance. Bert Bakker, MD, PhD. Senior Vice President, Medical Affairs. Michael Burdick, RAC. Senior Vice President, Regulatory Affairs. George Bright, MD. Vice President, Clinical Development. Vice President, Global Clinical Operations. Vice President, Marketing. Vice President, Manufacturing. Gregory S. Yedinak. Rajendra Mohabir, PhD.
TOTAL LINKS TO THIS WEBSITE
8
ベクター IR・会社情報 – ソフト登録数国内最大規模のオンラインソフトウェア流通サイトを運営する株式会社ベクターのIR・会社情報
平成30年3月期 第3四半期決算短信 日本基準 非連結. セカイ系ドラマチックRPG アビストライブ サービス開始から4日間で新規登録者数が100,000人を突破. セカイ系ドラマチックRPG アビストライブ 2017年11月30日 木 配信を開始.
Veeco Instruments, Inc. - Investors
August 17, 2015. Veeco’s process equipment solutions enable the manufacture of LEDs, flexible OLED displays, power electronics, compound semiconductors, hard drives, semiconductors, MEMS and wireless chips. We are the market leader in MOCVD, MBE, Ion Beam, Wet Etch single wafer processing and other advanced thin film process technologies. Click here to watch our corporate video. August 3, 2015. Veeco Reports Second Quarter 2015 Financial Results. July 30, 2015. July 28, 2015. 2014 10-K (PDF 1.54 MB.
VeriFone Global - IR - Investor Relations Home
Annual Report and Proxy. We are a leading global provider of technology that enables electronic payment transactions and value-added services at the point of sale. Since 1981, we have designed and marketed system solutions that facilitate the long-term shift toward electronic payment transactions and away from cash and checks. We have one of the leading electronic payment solutions brands and are one of the largest providers of electronic payment systems worldwide. For Non-GAAP Financial Measures.
Veritex Bank - Overview
What does it mean to be honest-to-goodness banking experts? It means you get exceptional customer service, smart banking choices and the peace of mind that comes with knowing we are invested in you and your community. From our eight banking centers across Dallas as well as our local home mortgage office, we're the community bank with a difference because we're making a difference in the community. 160; 0.55. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. March 09, 2015. July 28, 2015. Sign up t...
Veritiv - Investors - Investor Overview
Currently no events at this time. Veritiv Announces Second Quarter 2015 Financial Results. Veritiv to Release Second Quarter 2015 Financial Results on August 13. Veritiv Featuring Solutions for Property Management Professionals at 2015 BOMA Every Building Conference and Expo. Veritiv Announces First Quarter 2015 Financial Results. Powered By Q4 Web Systems.
Investor Overview - Versartis
Annual Reports and Proxies. Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA. 4:00 PM ET on Aug 17, 2015. Delayed at least 20 minutes. Aug 11, 2015. Versartis to Host Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency. Aug 4, 2015. View all press releases ». Canaccord ...
Vestas Wind Systems A/S - Mobile Investor
5:04 PM ET - Aug 7, 2015. Jul 9, 2015. Information in the market regarding project in the USA. Jun 30, 2015. Vestas receives 108 MW order in the USA. Jun 30, 2015. Vestas receives 274 MW order in the USA. Jun 30, 2015. Vestas receives 155 MW order in the USA. Jun 29, 2015. Information in the market regarding MHI Offshore Wind and an offshore project in Denmark. Nov 7, 2014. Disclosure of Q3 2014. Aug 20, 2014. Disclosure of Q2 2014. May 9, 2014. Disclosure of Q1 2014. Mar 24, 2014. Feb 28, 2014.
Investor Relations Overview
105 Corporate Center Blvd. Outdoor and Action Sports. VF Licensed Sports Group. Outdoor and Action Sports. VF Corporation Resources & Media. News / Events / Presentations. News and Media Inquiries. Associate Ethics and Benefits. Slide" data-cycle-swipe="true" data-cycle-timeout=0 data-cycle-log=false data-cycle-pager=" .pager" data-cycle-prev=" .prev" data-cycle-next=" .next". Deliver consistent, long-term value to shareholders by creating sustainable, profitable growth for our brands. Dec 19, 2016.
Viacom Inc. - Investor Relations
VIAB (Class B Stock). Data as of 03/29/18 4:00 PM ET. Minimum 20 minute delay. Deutsche Bank 26th Annual Media, Telecom and Business Services Conference. 03/5/18 at 1:40 PM ET. 1st QUARTER 2018 EARNINGS MATERIALS. 1st Quarter '18 Earnings Trending Schedules. 1st Quarter '18 Earnings Presentation. 1st Quarter '18 Earnings Press Release. Mar 26, 2018. Viacom Announces Strategic Partnership with Trevor Noah's Day Zero Productions. Mar 24, 2018. VIACOM'S USE OF SOCIAL MEDIA. Frequently Asked Questions (FAQs).
VietstockIR- Bình chọn Top 5 DNNY có hoạt động IR tốt nhất năm 2016
Tổ chức tham gia. Bình chọn top 5 dnny. Có hoạt động ir tốt nhất 2016. KHẢO SÁT TOP 5 DNNY CÓ HOẠT ĐỘNG IR TỐT NHẤT 2016. Hạn cuối tham gia khảo sát 05/10/2016. Chương trình Bình chọn doanh nghiệp niêm yết có hoạt động IR tốt nhất. Là chương trình được xây dựng định kỳ hàng năm nhằm mục đích chọn ra những doanh nghiệp niêm yết có hoạt động quan hệ nhà đầu tư (IR - Investor Relations) xuất sắc nhất. Bình chọn đã diễn ra. LỄ TRAO GIẢI 2014. LỄ TRAO GIẢI 2014. LỄ TRAO GIẢI 2015. LỄ TRAO GIẢI 2014.
Viking Therapeutics – Investors – Overview
VK5211 for Hip Fracture. Thyroid beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. 160; 0.46. Data as of 08/17/15 3:59 pm ET. Minimum 20 minute delay. Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update. Viking Therapeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemia and Fatty Liver Disease. SAN DIEGO, CA - (Marketwired) - 07/14/15 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
SOCIAL ENGAGEMENT